Who is sponsoring NCT04255823?

NCT04255823 is sponsored by Nantes University Hospital.

What drugs are being tested in NCT04255823?

Interventions in NCT04255823: General practitioner and Patient receive informations related to PPI deprescribing., Only General practitioner receive informations related to PPI deprescribing..

What condition does NCT04255823 study?

NCT04255823 studies Proton Pump Inhibitors, Deprescription.

Is NCT04255823 still recruiting?

NCT04255823 is currently completed. Last updated 22 April 2024.

Last reviewed 2024-04-22 · How we verify

NCT04255823: DeprescrIPP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of a Multi-faceted Intervention to Deprescribe Proton Pump Inhibitors (PPI) in Primary Care: a Population-based, Pragmatic, Cluster-randomized Controlled Trial.

Completed NA Last updated 22 April 2024

What this trial tests

NA trial testing General practitioner and Patient receive informations related to PPI deprescribing. in Proton Pump Inhibitors in 34,000 participants. Completed in 15 December 2021.

Timeline

29 September 2020

Primary endpoint
15 December 2021

15 December 2021

Quick facts

Lead sponsor	Nantes University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	health services research
Enrollment	34,000
Start date	29 September 2020
Primary completion	15 December 2021
Estimated completion	15 December 2021
Sites	1 location across France

Drugs / interventions tested

General practitioner and Patient receive informations related to PPI deprescribing.
Only General practitioner receive informations related to PPI deprescribing.

Conditions studied

Proton Pump Inhibitors — all drugs for Proton Pump Inhibitors →
Deprescription — all drugs for Deprescription →

Sponsor

Nantes University Hospital

Who can join

18 and older, any sex, with Proton Pump Inhibitors or Deprescription. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Deprescribing is defined as "the process of withdrawal of an inappropriate medication, supervised by a health care professional with the goal of managing the polypharmacy and improving outcomes". Inappropriate use of proton pump inhibitors (PPI) is associated with severe adverse drug reactions and a major economic impact. Deprescribing should be considered when inappropriate prescription of PPI is identified. DeprescrIPP is a pragmatic population-based cluster-randomized trial conducted in primary care. It will assess the efficacy and effectiveness of a multi-faceted intervention (on patients and general practitioners) to deprescribe PPI.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Effectiveness of a multi-faceted intervention to deprescribe proton pump inhibitors in primary care: protocol for a population-based, pragmatic, cluster-randomized controlled trial.
Nguyen-Soenen J, Rat C, Gaultier A, Schirr-Bonnans S, et al · · 2022 · cited 13× · PMID 35177042 · DOI 10.1186/s12913-022-07496-3
Deprescribing Intervention and Reduction of Proton Pump Inhibitor Use in Primary Care: A Cluster Randomized Clinical Trial.
Fournier JP, Gaultier A, Riche VP, Tessier P, et al · · 2026 · cited 1× · PMID 41973459 · DOI 10.1001/jamainternmed.2026.0584
Development and validation of a training course on proton pump inhibitor deprescription for general practitioners in a rural continuing medical education program: a pilot study.
Esparbes L, Escourrou E, Birebent J, Buscail L, et al · · 2024 · PMID 39465370 · DOI 10.1186/s12909-024-06215-2

Verify or expand the search:

Other recruiting trials for Proton Pump Inhibitors

Currently open trials in the same condition.

NCT06129474 — Deprescribing Inappropriate Proton Pump Inhibitors · NA · recruiting
NCT05582174 — PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers · Phase 4 · recruiting

Other Nantes University Hospital trials

Trials by the same sponsor.

NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04255823 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
Last refreshed: 22 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04255823.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing